Abstract. Understanding factors associated with more rapid bone mineral loss among aging women is important for establishing preventive strategies for intervention. This study reports factors associated with the 5-year change in radial bone mineral density (BMD) determined prospectively in 435 women aged 55-80 years at baseline. The baseline stUdy included measure-2 ment of radial BMD (gm/cm) by'single photon densitometry and personal interview. The baseline protocol was replicated 5 years later in a follow-up study. Women with a lower baseline weight or Quetelet index, smaller triceps skinfold and less arm muscle area had significantly greater 5-year bone loss (p = 0.001). Current users of estrogens had less radial bone loss (2.8% vs 7.3%, p = 0.0005) than women not currently using estrogens. Current users of estrogen had significantly less 5-year loss ff use had been for 5 years or longer (-1.0% vs -6.9%, p --0.05). Current users of the thiazide class of medications had less 5-year radial bone loss (5.0% vs 7.4%, p = 0.0035) than women without current thiazide use. Baseline dietary calcium, alcohol consumption and smoking were not associated with BMD change. This suggests that greater body size, and current use of estrogens or thiazide antihypertensives are associated with less radial bone mass toss in a 5-year period among postmenopausal women.
Introduction
Because of the social, health and economic impact of fractures, loss of bone mass and osteoporosis are important. The lifetime risk of hip fracture is estimated to be 15% in women and 5% in men; this is equivalent to the lifetime risk of developing breast, uterine and ovarian cancer in women and prostate cancer in men. The cost of health care associated with fractures was estimated to be $6.1 billion in 1984 [1, 2] and has been projected to be more than $100 billion by the year 2020 [3] , driven, in part, by the increasing proportion of elderly persons in society.
The magnitude of bone loss is important in understanding the process that may ultimately lead to fracture. There have been few prospective studies of bone mineral density (BMD) which characterized bone loss with aging using contemporary, precise bone measurement methodology [4] [5] [6] [7] [8] [9] and which considered multiple risk factors for rate of bone loss simultaneously. We have recently reported that the average 5-year radial bone mineral loss was 6% among women aged 55-80 years at baseline [9] . Understanding factors associated with more rapid bone mineral loss among aging women is important for establishing preventive strategies for intervention.
This report describes those factors associated with 5-year change in radial BMD determined prospectively in women who were aged 60-85 years at follow-up measurement. This study is an extension of our earlier work and includes data from an additional 164 women, making a total study group of 435 elderly women.
Methods
The study population included women living in three demographically similar rural communities in northwest Iowa. State-specific census data from 1970 and 1980 indicated that the communities were similar with respect to population size, age distribution, proportion of foreign-born subjects, mean income and occupational categories. The population of each community was less than 2000 persons. The municipal drinking water supplies in the three communities had divergent calcium and fluoride content. The drinking water in one community had an elemental calcium concentration of 15 +_ 3 rag/1 and a naturally occurring fluoride concentration of 4+0.1 mg/1; drinking water in the second community averaged 375 + 8 mg/1 elemental calcium and was fluoridated to a level of i rag/l; drinking water in the third community had an average elemental calcium content of 67 _+ 4 rag/1 and was fluoridated to a level of 1 mg/1, as determined by the state public health laboratory. Women were eligible for the baseline study if they had lived in their respective communities for the 5 years prior to the survey. All participants were ambulatory and had not experienced wrist or forearm fractures in the 2 years prior to baseline radial BMD assessment. All participants were aged 55-80 years at the baseline measurement, postmenopausal, and of northern European origin, as has been described [10] . Baseline information was gathered in the communities from May to August 1983 or from May to August 1984. Each woman was re-examined exactly 5 years after her initial measurement. To simplify presentation, all data collected in 1983 or 1984 will be labeled 'baseline' while data collected in 1988 or 1989 will be labeled 'follow-up'.
Selected characteristics for women who participated in both the baseline and follow-up studies (n = 435) were compared with the characteristics of those women who participated only in the baseline study because they had moved from their communities (n = 26), died (n = 33) or refused participation at follow-up (n = 29). The characteristics are summarized in Table 1 . Participants in the follow-up study had greater radial BMD, were younger, and had been menopausal for a shorter time (p = 0.05).
Bone Mass and Physical Measurements
Radial bone mass was measured, at both time points, using a Norland 278 photon absorpiometer (Norland, r25 Madison, WI) with a I source. Bone mass, exl~ressed as the bone mineral to bone width ratio (g/cm0, was measured distally at a site one-third the distance between the styloid process and the olecranon, a site which is at least 95% cortical bone. The same procedures and instrumentation were used at both baseline and follow-up examinations. A single observer measured bone mass of all persons at baseline while a different single observer measured bone mass at followup. Bone mass loss was calculated on an individual basis not on a summary basis across the entire group of women.
At each time point, one trained observer measured each participant for height, weight, triceps skinfold thickness and mid-arm circumference according to standardized procedures. Subjects were weighed in light clothing without shoes to the nearest 0.1 kg using an electronic scale; height was measured to the nearest 0.1 cm using an anthropometric plane and scale. Triceps skinfold thickness was measured with Lange calipers and recorded in millimeters using the mean of three consecutive readings; mid-arm circumference was measured to the nearest 0.1 cm and used with triceps skinfold to estimate muscle area. Quetelet index was calculated as weight/height 2 in kilograms and meters, respectively.
Nutrient Intake Assessment
At baseline, each partidpant responded to a food frequency instrument to characterize intake of foods high in calcium and vitamin D; they also recalled their intake of food over the preceding 24 h. Interviewers were trained in techniques to elicit recall of food and beverage intake, including the use of color photographs to enhance the recall of portion sizes. To promote accuracy, food and beverage intakes from each recall and the food frequency were independently coded twice. The correlation between calcium intake at baseline estimated by the two methods was 0. [11] or on other information sources about fortified products such as milk and dry cereals. Nutrient values for the food frequency were based on the algorithms from the NCI food frequency [12] .
The interviewer gathered information about nutritional supplements by observing the labels of currently used preparations and asking the participant to recall the number, frequency and individual duration of use of the preparations. These estimates of supplements were added to nutrient intake from food and water to calculate total intake.
Reproduction, Climacteric and Medical History
Interviews at baseline and follow-up included questions about estrogen replacement therapy (including time intervals of use) and surgical menopause. Detailed medication use histories were taken at both points in time. We compared responses to questions about ever use of per±menopausal estrogen (Premarin, Wyeth) and the duration of that use as reported at both baseline and follow-up interviews. Data analysis describing a role for estrogen was limited to those women who were consistent in their report of estrogen use and whose reported duration of use was congruent (+ 1 year).
Procedures followed were approved by the Universities of Michigan and Iowa Committees on Human Experimentation and Radiation Protection Subcommittees.
Data Analysis
Chi-squared tests of homogeneity were used to ascertain whether women who did not participate in the follow-up were different in terms of marital status, selfperception of health, education, parity and medication use compared with women who did participate. Students' t-test and analysis of variance were used to test whether baseline measures of age, body size, age of menopause and BMD were comparable between respondents and non-respondents in the re-examination.
All continuous variables were evaluated for normalcy of distribution; those variables identified as not having a normal distribution (such as nutrient intake) were either logarithm transformed or changed into categorical variables (such as alcohol intake). Continuous radial BMD variables were: radial BMD (1983), radial BMD (1988), and 5-year BMD change expressed as the difference between measured BMD in 1983 and 1988 (g/cm 2) and the percentage change in 5 years.
Univariate summaries were produced for continuous BMD variables, overall and according to community. Ftest values from multiple variable linear regression and logistic regression analyses were used to test for a difference in bone and physical measurements according to community status. Because a community difference in BMD was identified, all subsequent analyses included adjustment for community. Multiple variable regression and multiple response conditional logistic regression analyses were used to assess relationships between 5-year BMD change and baseline BMD value, body size measures, medication use and nutrient intake, after adjusting for age [13, 14] .
Results
The mean radial BMD at baseline and follow-up, as well as the difference (both absolute and percentage) between baseline and follow-up measures, are shown in Table 2 . There is remarkable consistency in associations between the risk factors and the two measures of 5-year bone mineral, the absolute change or percentage change; therefore, risk factor associations in this paper will be related to percentage loss for ease of presentation.
Baseline radial BMD was highly associated (r 2 = 0.86, p < 0.0001) with radial BMD observed at followup, after adjusting for age and community of residence. However, there was no important relationship between baseline BMD and percentage BMD change (p = 0.30), suggesting that lower BMD was not a risk factor for more rapid bone loss in a 5-year period among women of this age group. We explored the possibility of a quadratic relationship between baseline radial BMD and percentage 5-year radial bone loss, and found no evidence of non-linearity when age or baseline radial BMD were evaluated using quadratic terms. Several measures of body size were evaluated as possible risk factors for increased rate of radical bone loss (Fig. 1) .
Ever use and duration of estrogen use were evaluated for possible impact on 5-year rate of radial bone loss. This analysis was undertaken among the 86% of women who were consistent reporters (i.e. consistent reports of whether or not they had ever used estrogens and the dates of use at baseline and follow-up). The consistently reporting group included current users at the time of follow-up investigation (n = 24), previous users (n = 71) and never users (n = 244); mean baseline age, Quetelet index and years of estrogen use are shown in Table 3 for each subgroup. As shown in Table 3 , following adjustment for age, community and body size, use of estrogens at follow-up was associated with less 5-year bone loss. Current users lost less radial bone mass (2.8% vs 7.3% and 7.4%, p = 0.005) than did women in either of the other two categories.
However, duration of estrogen use was an important factor among current users (see Table 4 ). Current users of estrogen had significantly less 5-year loss is use had been for 5 years or longer (-1.0% vs -6.9%,p = 0.05). BMD or 5-year BMD loss among past users of estrogens. We compared the bone loss of women in four categories of thiazide use as shown in Table 5 . There was significantly less 5-year bone loss among women who had a current thiazide prescription. When women who had never used thiazides and past-only users (n = 343) were compared with women who reported current use (n = 88), the current users had less 5-year radial bone loss (7.4% vs 5.0%, p = 0.0035).
Factors which might influence this relationship are shown in Table 6 . After adjustment for age, commun- Baseline intakes of protein, dietary/supplement calcium and dietary/supplement vitamin D intake were not predictive of 5-year radial bone percentage change. The age-adjusted models of bone change and these nutrients were non-significant whether dietary intake was estimated from a food frequency instrument or a 24-h recall. Likewise, there was no relationship when calcium intake was expressed per 1000 kilocalories and related to percentage bone mass change.
As shown in Table 7 , calcium and vitamin D intake were each dichotomized with Recommended Dietary Allowance as the criterion [calcium <800 mg (n = 199) vs >1800 mg (n = 233); vitamin D <400 IU (n = 269) vs t>400 IU (n = 163)]. There was no significant relationship between radial bone loss and either two-level variable. When women were categorized by their joint calcium and vitamin D intake [dietary calcium <800 mg and vitamin D <400 IU (n = 130); calcium intake 1>800 mg but vitamin D <400 IU (n = 139); calcium <800 mg and vitamin D ~>400 IU (n = 69); and calcium intake />800 mg with vitamin D I>400 IU (n = 94)], no relationship was found between calcium/vitamin D intake and percentage bone loss.
As shown in Table 8 , there was no association of alcohol intake with bone change, but women with greater alcohol use were younger and had fewer years since menopause. There was no association between alcohol consumption (never drank, less than 4 drinks/ week, or 4 or more drinks/week) and rate of bone mineral change after adjusting for age, menopause, body size and community.
Smoking was not associated with 5-year bone change when categorized as never smoker, previous smoker or smoker in the 5-year interval (p = 0.72). As shown in Table 9 , classification according to pack-years was not associated with a significant difference in 5-year bone loss. The median number of packs smoked in this population is 4500.
Reproduction and the climacteric were evaluated for association with 5-year rate of bone loss. We observed no association between age at menopause or time since menopause and 5-year BMD change following adjustment for age, body size and community. When women were classified according to parity (nulliparous, parity >1-3 or parity >3 live births), there was no association with rate of change. Similarly, women who had had two or more miscarriages had no difference in 5-year bone loss among these postmenopausal women. 
Discussion
Given the limited number of interventions currently available to treat bone loss with aging, identification of factors which minimize 5-year bone change is important. Estrogens have been identified as slowing or curtailing bone loss in a number of clinical studies (see [15] and [16] for reviews). We have found that current estrogen use was associated with less bone loss in a group whose average age is 63 years, which is 15 years after the average age of menopause in this population.
Other studies, including those using estradiol implants, have confirmed a positive effect of estrogens on bone mineral density and fracture among older women [17] [18] [19] . It is important to note that the most potent effect of these estrogens appeared to be associated with current use, but that the duration of current use had to be in excess of 5 years. These data suggest that prior use of estrogens does not delay bone loss beyond the time of use, even if that prior use was of relatively long duration. Furthermore, these data suggest that protection is associated with estrogen even in the period of time beyond the perimenopause. Although there is relatively low prevalence of estrogen use in this study, this finding in a community-based population supports an accumulating body of literature. We observed that current thiazide use was associated with less radial bone loss, though the reduction was not as substantial as that observed with the use of estrogens. The impact of thiazides was associated with current but not pre~ious thiazide use. This impact is also independent of current estrogen use as only 4 women were using thiazides and estrogens concurrently. It has been proposed that thiazide use might forestall bone loss by curtailing urinary calcium excretion [20] . There was no difference in baseline dietary calcium intake between users and non-users of thiazides. Therefore, the contrast in rate of 5-year bone loss between current and past thiazide users would suggest that urinary calcium loss resumed its previous rate among those women who were past users of thiazides. While we [21] and others [22] have previously reported an association, a clinical trial of thiazide use suggested this might be a transitory effect [231.
It is well recognized that body size is associated with level of bone mass, and we observed that measures of greater body size, including measures of both obesity and muscle area, were associated with less 5-year bone change. Whether obese women have greater bone mass because of aromatization of adrostenedione to estrone in the adipocytes [24] or a mechanical role associated with bone loading has not been defined. Ribot et al. [25] have reported a protective effect of obesity in postmenopausal bone loss. However, levels of estradiol and testosterone did not differ between obese and nonobese postmenopausal women, suggesting that body size may have a mechanical rather than a hormonal role in bone change.
We can only speculate as to why dietary calcium and vitamin D intake at baseline were not associated with subsequent rates of radial bone change. While many may be disappointed at our failure to find a relationship between bone mass change and calcium intake, the lack of an observed relationship is consistent with many other studies which included various study designs [26] . Several factors may account for these findings. First, in a widely cited study of calcium supplementation [27] no effect of supplementation was observed in women whose baseline intake exceeded 400 mg calcium per day. Further, the most promising supplement was in a citrate complex, a chemical configuration not widely available in foods. Second, assessment of calcium, like that of other dietary nutrients, has been plagued with methodological problems. For example, Sempos et al. [28] have estimated that six 24-h recalls per individual are needed to assure that the efficiency of estimating the true population correlation coefficient is greater than or equal to 90%. A single 24-h recall used to estimate an individual's calcium intake has an efficiency of 50%. Thus, findings from studies based on 24-h food recalls should be regarded with caution unless accompanied by other methodologies. We took this approach to evaluating diet in our study population, and utilized both the 24-h recall method and the food frequency method. In addition, calcium intake from supplements and drinking water were considered. Even when considering vitamin D contribution or adjustment for total calories consumed, we could not identify a statistically significant relationship with bone mineral change in this wellnourished population.
This prospective study and its implementation have several limitations. It describes cortical bone of the radius measured by single photon absorptiometry and does not provide measures of the spine and hip. BMD was measured at the radius with single photon densitometry for historical reasons. When the study began, single photon densitometry was the only technique available with minimal radiation exposure that was acceptable to the ethics committee for communitybased studies. It is a highly precise methodology, a characteristic desirable in longitudinal studies with repeated measurements, where each subsequent measure can be associated with potential for error. The follow-up examination included measures of both radial BMD by single photon densitometry and femoral neck BMD by dual photon absorptiometry.
A second limitation is the relatively short 5-year follow-up -a limitation shared with many studies. There are two other reported longitudinal studies of BMD, using the more precise photon densitometric methodology, which has reported data from a longer time interval. The study by Johnston et al. [4, 5] reports an average follow-up of approximately 6.5 years. The study of 73 women by Falch and Sandvik [29] was 10 years in duration.
Loss to follow-up is a major concern in all prospective studies. The refusal rate for re-examination was extremely tow (6%), although an additional 12% of the baseline study group did not participate because of death (7%) or moving (5%).
In summary, we reiterate that understanding the factors associated with more rapid bone mineral loss among aging women is important for establishing preventive strategies for intervention and risk profiles for women who may need frequent follow-up. Baseline radial BMD was highly associated with follow-up radial BMD; however, there was no relationship between baseline BMD and percentage BMD change, suggesting that lower BMD was not a risk factor for more rapid bone loss in a 5-year period among these women. These data suggest that greater body size, and current use of estrogens or thiazide antihypertensive medication are associated with less radial bone mass loss in a 5-year period among postmenopausal women. Baseline dietary calcium, alcohol consumption and smoking were not associated with BMD change.
